Henry S Heine,
PRG DIR & RES ASO PROF
Department:
MD-INST FOR THERAPEUTIC INNOV
Business Phone:
(407) 313-7062
Business Email:
henry.heine@medicine.ufl.edu
Teaching Profile
Courses Taught
2018-2021
GMS5905 Special Topics in Biomedical Sciences
2018
GMS7979 Advanced Research
Research Profile
Open Researcher and Contributor ID (ORCID)
0009-0002-4746-4892
Publications
Academic Articles
2024
A Resistance-Evading Antibiotic for Treating Anthrax.
Research square.
[DOI] 10.21203/rs.3.rs-3991430/v1.
[PMID] 38585816.
2024
Engineered antibodies targeted to bacterial surface integrate effector functions with toxin neutralization to provide superior efficacy against bacterial infections.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2024.09.23.24313920.
[PMID] 39398995.
2024
Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistant Burkholderia pseudomallei in a murine infection model
Antimicrobial Agents and Chemotherapy.
[DOI] 10.1128/aac.01295-24.
2024
Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis.
Antimicrobial agents and chemotherapy.
68(9)
[DOI] 10.1128/aac.00595-24.
[PMID] 39133023.
2024
Tolfenpyrad Derivatives Exhibit Potent Francisella-Specific Antibacterial Activity without Toxicity to Mammalian Cells In Vitro.
ACS infectious diseases.
10(11):3902-3914
[DOI] 10.1021/acsinfecdis.4c00547.
[PMID] 39356820.
2023
The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with Aerosolized Burkholderia pseudomallei.
Antibiotics (Basel, Switzerland).
12(3)
[DOI] 10.3390/antibiotics12030506.
[PMID] 36978372.
2023
Tolfenpyrad displays Francisella-targeted antibiotic activity that requires an oxidative stress response regulator for sensitivity.
Microbiology spectrum.
11(6)
[DOI] 10.1128/spectrum.02713-23.
[PMID] 37800934.
2021
In Vitro and In Vivo Characterization of Tebipenem (TBP), an Orally Active Carbapenem, against Biothreat Pathogens.
Antimicrobial agents and chemotherapy.
65(5)
[DOI] 10.1128/AAC.02385-20.
[PMID] 33593844.
2020
Validated Methods for Removing Select Agent Samples from Biosafety Level 3 Laboratories.
Emerging infectious diseases.
26(11):2586-2590
[DOI] 10.3201/eid2611.191630.
[PMID] 33079040.
2019
GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.
Antimicrobial agents and chemotherapy.
63(12)
[DOI] 10.1128/AAC.00834-19.
[PMID] 31548183.
2017
Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.
Antimicrobial agents and chemotherapy.
61(9)
[DOI] 10.1128/AAC.00788-17.
[PMID] 28696235.
2017
In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods.
Antimicrobial agents and chemotherapy.
61(9)
[DOI] 10.1128/AAC.00612-17.
[PMID] 28674048.
2017
The Fluorocycline Tp-271 Is Efficacious in Models of Aerosolized Bacillus Anthracis Infection in Balb/C Mice and Cynomolgus Macaques
Antimicrobial Agents and Chemotherapy.
61(10)
[DOI] 10.1128/AAC.01103-17.
2017
The Fluorocycline Tp-271 Is Efficacious in Models of Aerosolized Francisella Tularensis Schu S4 Infection in Balb/C Mice and Cynomolgus Macaques
Antimicrobial agents and chemotherapy.
61(8)
[DOI] 10.1128/AAC.00448-17.
[PMID] 28559261.
2016
Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.
Antimicrobial agents and chemotherapy.
60(3):1834-40
[DOI] 10.1128/AAC.02887-15.
[PMID] 26824958.
2015
In vitro antibiotic susceptibilities of Yersinia pestis determined by broth microdilution following CLSI methods.
Antimicrobial agents and chemotherapy.
59(4):1919-21
[DOI] 10.1128/AAC.04548-14.
[PMID] 25583720.
2014
Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
Antimicrobial agents and chemotherapy.
58(6):3276-84
[DOI] 10.1128/AAC.02420-14.
[PMID] 24687492.
2013
Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice.
Antimicrobial agents and chemotherapy.
57(5):2010-5
[DOI] 10.1128/AAC.02504-12.
[PMID] 23403418.
2012
Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.
Antimicrobial agents and chemotherapy.
56(1):513-7
[DOI] 10.1128/AAC.05724-11.
[PMID] 22064542.
2012
Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Antimicrobial agents and chemotherapy.
56(3):1229-39
[DOI] 10.1128/AAC.01109-10.
[PMID] 22155821.
2011
Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model.
Antimicrobial agents and chemotherapy.
55(6):2623-8
[DOI] 10.1128/AAC.01374-10.
[PMID] 21486959.
2011
Comparison of Etest method with reference broth microdilution method for antimicrobial susceptibility testing of Yersinia pestis.
Journal of clinical microbiology.
49(5):1956-60
[DOI] 10.1128/JCM.00142-11.
[PMID] 21411569.
2011
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Antimicrobial agents and chemotherapy.
55(2):822-30
[DOI] 10.1128/AAC.00818-10.
[PMID] 21115791.
2010
Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
Antimicrobial agents and chemotherapy.
54(3):991-6
[DOI] 10.1128/AAC.00820-09.
[PMID] 20047912.
2010
Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
Antimicrobial agents and chemotherapy.
54(10):4471-3
[DOI] 10.1128/AAC.00210-10.
[PMID] 20643899.
2010
Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis.
Molecular and cellular probes.
24(3):154-60
[DOI] 10.1016/j.mcp.2010.01.003.
[PMID] 20100564.
2010
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
Antimicrobial agents and chemotherapy.
54(5):1678-83
[DOI] 10.1128/AAC.00737-08.
[PMID] 20145081.
2009
Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy.
53(11):4718-25
[DOI] 10.1128/AAC.00802-09.
[PMID] 19687233.
2008
Application of carbohydrate microarray technology for the detection of Burkholderia pseudomallei, Bacillus anthracis and Francisella tularensis antibodies.
Carbohydrate research.
343(16):2783-8
[DOI] 10.1016/j.carres.2008.05.021.
[PMID] 18558401.
2008
Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
Antimicrobial agents and chemotherapy.
52(9):3350-7
[DOI] 10.1128/AAC.00360-08.
[PMID] 18606841.
2008
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
Antimicrobial agents and chemotherapy.
52(11):3973-9
[DOI] 10.1128/AAC.00453-08.
[PMID] 18725437.
2008
Petrobactin is produced by both pathogenic and non-pathogenic isolates of the Bacillus cereus group of bacteria.
Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine.
21(5):581-9
[DOI] 10.1007/s10534-008-9144-9.
[PMID] 18459058.
2008
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
Antimicrobial agents and chemotherapy.
52(7):2486-96
[DOI] 10.1128/AAC.01439-07.
[PMID] 18458134.
2007
Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.
The Journal of infectious diseases.
196(5):782-7
[PMID] 17674322.
2007
Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
Antimicrobial agents and chemotherapy.
51(4):1373-9
[PMID] 17296745.
2007
Novel semisynthetic derivative of antibiotic Eremomycin active against drug-resistant gram-positive pathogens including Bacillus anthracis.
Journal of medicinal chemistry.
50(15):3681-5
[PMID] 17608397.
2007
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
Antimicrobial agents and chemotherapy.
51(12):4351-5
[PMID] 17875992.
2006
Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.
Proceedings of the National Academy of Sciences of the United States of America.
103(20):7813-6
[PMID] 16672361.
2005
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
Antimicrobial agents and chemotherapy.
49(12):5099-106
[PMID] 16304178.
2001
In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test.
Antimicrobial agents and chemotherapy.
45(7):2119-21
[PMID] 11408233.
Grants
Aug 2024
– Sep 2024
In vitro microbiological evaluation of Acurx DNA pol IIIC compounds against Category A Bacterial pathogens (B. anthracis)
Role: Principal Investigator
Funding: ACURX PHARMACEUTICALS
Jul 2024
– Dec 2024
Batelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
Role: Principal Investigator
Funding: BATTELLE MEMORIAL INST
via DEFENSE THREAT REDUCTION AGENCY
Nov 2023
– Mar 2024
In Vitro Microbiological Evaluations of Delafloxacin Against Category A and B Bacterial Pathogen Panels
Role: Co-Investigator
Funding: Melinta Therapeutics,Inc
via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Apr 2023
ACTIVE
In vitro testing of 100 isolates of B. pseudomallei
Role: Principal Investigator
Funding: VENATORX PHARMACEUTICALS
via BIOMEDICAL ADVANCED RES & DEVLPMT AUTHOR
Sep 2022
ACTIVE
Battelle Accelerated Therapeutics for the Treatment of Emerging and Multidrug-Resistant Bacteria (BAT-TEAM)
Role: Principal Investigator
Funding: BATTELLE MEMORIAL INST
via DEFENSE THREAT REDUCTION AGENCY
Apr 2022
– Mar 2024
In Vitro Microbiological Evaluations of Antibody-Drug Conjugates (ADCs) Against Category A and B Bacterial Pathogen Panels
Role: Co-Investigator
Funding: CENTER FOR DISCOVERY AND INNOVATION
via NATL INST OF HLTH NIAID
Feb 2022
– Jun 2022
Evaluation of Lefamulin dose to survival in mice following aerosol exposure to F. tularensis SchuS4
Role: Principal Investigator
Funding: NABRIVA THERAPEUTICS
Feb 2022
– Mar 2022
In Vitro Microbiological Evaluations of Medinamycin (MedM), MsbA inhibitor P2129, MedM + SPR741, and MsbA inhibitor P2129 + SPR741 Against Category A and B Bacterial Pathogen Panels
Role: Principal Investigator
Funding: PROKARYOTICS
Jan 2022
– Jul 2023
Merck Study Agreement
Role: Principal Investigator
Funding: MERCK SHARP & DOHME
Aug 2021
– Aug 2022
In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens
Role: Principal Investigator
Funding: NABRIVA THERAPEUTICS
Mar 2021
ACTIVE
Development of CZ-02s (AIIPS), a New Class of Antibacterial for the Treatment of Drug-Resistant Bacterial Infections, including those caused by Multidrug-Resistant Yersinia pestis, Francisella tularensis, and Burkholderia mallei
Role: Principal Investigator
Funding: ADVANCED TECHNOLOGY INTERNATIONAL
via DEFENSE THREAT REDUCTION AGENCY
Feb 2021
– Jun 2021
Evaluation of air purification methods for SARS-CoV-2
Role: Co-Investigator
Funding: HELEN OF TROY
Feb 2021
– May 2021
Teixobactin Development for Anthrax
Role: Principal Investigator
Funding: NOVOBIOTIC PHARMACEUTICALS
via NATL INST OF HLTH NIAID
Nov 2020
– Dec 2021
Project Bioshield
Role: Co-Investigator
Funding: SPERO THERAPEUTICS
Oct 2020
– Nov 2020
MICs for Wockhardt WCK-5222
Role: Principal Investigator
Funding: WOCKHARDT BIO AG
May 2020
– Jul 2020
KBP Biosciences Research Agreement – In vitro microbiological evaluation of IND antibiotics versus Category A and B pathogens
Role: Principal Investigator
Funding: *KBP BIOSCIENCES USA
Apr 2020
– Sep 2024
Battelle Subcontract 778380 SAB Year 1
Role: Principal Investigator
Funding: BATTELLE MEMORIAL INST
via DEFENSE THREAT REDUCTION AGENCY
Feb 2020
– Sep 2022
Evaluation of antimicrobial peptides for Biodefense
Role: Principal Investigator
Funding: UNIV OF TEXAS AUSTIN
via DEFENSE THREAT REDUCTION AGENCY
Apr 2019
– Aug 2019
EPDG-15-GC072-S-0001 Task 4.7 Dose Loading Efficacy Study
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Apr 2019
– Aug 2019
EPDG-15-GC072-S-0001 Task 4.7 PK Study
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Jan 2019
– Oct 2020
In vitro testing of the 40 isolate panel of B. pseudomallei isolates
Role: Principal Investigator
Funding: VENATORX PHARMACEUTICALS
via DEFENSE THREAT REDUCTION AGENCY
Nov 2018
– Apr 2019
In Vitro Microbiological Evaluation of Polymyxin Analogs versus Category A and B Pathogens
Role: Principal Investigator
Funding: SPERO THERAPEUTICS
via NATL INST OF HLTH NIAID
Jul 2018
– Mar 2019
Confirmatory Efficacy Study in Bp Infected Mice
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Feb 2018
– Oct 2018
Evaluation of the improved GC-072 formulation plasma and lung ELF PK in uninfected and the Bp infected mice model
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Nov 2017
– Jun 2018
Evaluation of single and twice daily dosing of EBX-205 on survival of mice following aerosol exposure to B.pseudomallei 1026b
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Nov 2017
– Jan 2018
Evaluation of EBX-205 against of B. Pseudomallei in virto
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Oct 2017
– Feb 2018
MIC90 determination of 2 ?-lactam inhancer antibacterial compounds from Wockhardt against sets of 30 strains each of Yersinia pestis, Francisella tularensis, Burkholderia mallei(12 strains) and Burkholderia pseudomallei.
Role: Principal Investigator
Funding: WOCKHARDT BIO AG
Sep 2017
– Dec 2017
Evaluation of EBX-205 dose to survival in mice following aerosol exposure to B. pseudomallei 1026b
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
Sep 2017
– Sep 2018
Pharmacokinetic analysis of nonhuman primate data for US Army
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Aug 2017
– Jan 2018
ANTIBIOTIC SUSCEPTIBILITY AND SPONTANEOUS RESISTANCE DEVELOPMENT FOR VARIOUS ISOLATES OF B. PSEUDOMALLEI
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Aug 2017
– Jan 2018
Exhibit N – MIC testing of BSC 3 extended MIC Panel in connection with Achaogens C-Scape project as outlined in University of Florida proposal ITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
Aug 2017
– Jan 2018
ITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
May 2017
– Aug 2017
Salary for protocol development and ACURO review
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Mar 2017
– May 2017
WITI Antibiotic Susceptibility Determinations
Role: Principal Investigator
Funding: ACHAOGEN
Oct 2014
– Dec 2017
HDTRA114-CBM-06-1-0052 titled GC-072: The First Oral Antibiotic for the Treatment of Acute Melioidosis and Select Agents
Role: Project Manager
Funding: EMERGENT BIOSOLUTIONS
via US DEPT OF DEFENSE
Sep 2014
– Dec 2016
Task 2.5 In Vivo Efficacy Study to Identify Most Effective Doses
Role: Principal Investigator
Funding: EMERGENT BIOSOLUTIONS
via DEFENSE THREAT REDUCTION AGENCY
Jul 2012
– Jul 2017
In Vitro Antibiotic Therapeutic Services in Support of protocol #AP-10-047G: Pharmokinetic and pharacodynamic analyses of intravenous Moxifloxican in Non-Human Primates using appropriate computer programs.
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Apr 2012
– Apr 2016
EVALUATION OF THE POTENTIAL OF GSK2140944 IN THE VIVO MURINEINHALATIONAL MODELS FOR YERSINIA PESTIS: Study #1
Role: Principal Investigator
Funding: GLAXOSMITHKLINE
via US DEPT OF DEFENSE
Contact Details
Phones:
- Business:
- (407) 313-7062
Emails:
- Business:
- henry.heine@medicine.ufl.edu
Addresses:
- Business Mailing:
-
RESEARCH ACADEMIC CENTER AT LAKE NONA
6550 SANGER RD
ITI
ORLANDO FL 328277445 - Business Street:
-
U. FLORIDA RESEARCH ACADEMIC CENTER AT LAKE
ITI, DEPT MEDICINE
ORLANDO FL 32832